Effect of selected nonsteroidal anti-inflammatory drugs on the viability of canine osteosarcoma cells of the D-17 line: in vitro studies

1Abdelrahim M., Baker C.H., Abbruzzese J.L., Safe S.: Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 2006, 98, 855–868. Abdelrahim M. Baker C.H. Abbruzzese J.L. Safe S. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation J Natl Cancer Inst 2006 98 855 86810.1093/jnci/djj232Search in Google Scholar

2Basha R., Ingersoll S.B., Sankpal U.T., Ahmad S., Baker C.H., Edwards J.R., Holloway R.W., Kaja S., Abdelrahim M.: Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors. Gynecol Oncol 2011, 122, 163–170. Basha R. Ingersoll S.B. Sankpal U.T. Ahmad S. Baker C.H. Edwards J.R. Holloway R.W. Kaja S. Abdelrahim M. Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors Gynecol Oncol 2011 122 163 17010.1016/j.ygyno.2011.03.014Search in Google Scholar

3Chen W.S., Wei S.J., Liu J.M., Hsiao M., Kou-Lin J., Yang W.K.: Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer 2001, 91, 894–899. Chen W.S. Wei S.J. Liu J.M. Hsiao M. Kou-Lin J. Yang W.K. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac Int J Cancer 2001 91 894 89910.1002/1097-0215(200102)9999:9999<894::AID-IJC1146>3.0.CO;2-#Search in Google Scholar

4Choi E.S., Shim J.H., Jung J.Y., Kim H.J., Choi K.H., Shin J.A., Nam J.S., Cho N.P., Cho S.D.: Apoptotic effect of tolfenamic acid in androgen receptor-independent prostate cancer cell and xenograft tumor through specificity protein 1. Cancer Sci 2011, 102, 742–748. Choi E.S. Shim J.H. Jung J.Y. Kim H.J. Choi K.H. Shin J.A. Nam J.S. Cho N.P. Cho S.D. Apoptotic effect of tolfenamic acid in androgen receptor-independent prostate cancer cell and xenograft tumor through specificity protein 1 Cancer Sci 2011 102 742 74810.1111/j.1349-7006.2011.01871.xSearch in Google Scholar

5Colon J., Basha M.R., Madero-Visbal R., Konduri S., Baker C.H., Herrera L.J., Safe S., Sheikh-Hamad D., Abudayyeh A., Alvarado B., Abdelrahim M.: Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Invest New Drugs 2011, 29, 41–51. Colon J. Basha M.R. Madero-Visbal R. Konduri S. Baker C.H. Herrera L.J. Safe S. Sheikh-Hamad D. Abudayyeh A. Alvarado B. Abdelrahim M. Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice Invest New Drugs 2011 29 41 5110.1007/s10637-009-9331-8Search in Google Scholar

6Eslin D., Sankpal U.T., Lee C., Sutphin R.M., Maliakal P., Currier E., Sholler G., Khan M., Basha R.: Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: A novel therapeutic agent for neuroblastoma. Mol Carcinog 2013, 52, 377–386. Eslin D. Sankpal U.T. Lee C. Sutphin R.M. Maliakal P. Currier E. Sholler G. Khan M. Basha R. Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: A novel therapeutic agent for neuroblastoma Mol Carcinog 2013 52 377 38610.1002/mc.21866Search in Google Scholar

7Grandemange E., Fournel S., Boisramé B.: Field evaluation of the efficacy of tolfenamic acid administered in one single preoperative injection for the prevention of postoperative pain in the dog. J Vet Pharmacol Ther 2007, 30, 503–507. Grandemange E. Fournel S. Boisramé B. Field evaluation of the efficacy of tolfenamic acid administered in one single preoperative injection for the prevention of postoperative pain in the dog J Vet Pharmacol Ther 2007 30 503 50710.1111/j.1365-2885.2007.00899.xSearch in Google Scholar

8Hillers K.R., Dernell W.S., Lafferty M.H., Withrow S.J., Lana S.E.: Incidence and prognostic importance of lymph node metastases in dogs with appendicular osteosarcoma: 228 cases (1986–2003). J Am Vet Med Assoc 2005, 226, 1364–1367. Hillers K.R. Dernell W.S. Lafferty M.H. Withrow S.J. Lana S.E. Incidence and prognostic importance of lymph node metastases in dogs with appendicular osteosarcoma: 228 cases (1986–2003) J Am Vet Med Assoc 2005 226 1364 136710.2460/javma.2005.226.1364Search in Google Scholar

9Khwaja F.S., Quann E.J., Pattabiraman N., Wynne S., Djakiew D.: Carprofen induction of p75NTR-dependent apoptosis via the p38 mitogen-activated protein kinase pathway in prostate cancer cells. Mol Cancer Ther 2008, 7, 3539–3545. Khwaja F.S. Quann E.J. Pattabiraman N. Wynne S. Djakiew D. Carprofen induction of p75NTR-dependent apoptosis via the p38 mitogen-activated protein kinase pathway in prostate cancer cells Mol Cancer Ther 2008 7 3539 354510.1158/1535-7163.MCT-08-0512Search in Google Scholar

10McKellar Q.A., Lees P., Gettinby G.: Pharmacodynamics of tolfenamic acid in dogs. Evaluation of dose response relationships. Eur J Pharmacol 1994, 253, 191–200. McKellar Q.A. Lees P. Gettinby G. Pharmacodynamics of tolfenamic acid in dogs Evaluation of dose response relationships. Eur J Pharmacol 1994 253 191 20010.1016/0014-2999(94)90191-0Search in Google Scholar

11Mullins M.N., Lana S.E., Dernell W.S., Ogilvie G.K., Withrow S.J., Ehrhart E.J.: Cyclooxygenase-2 expression in canine appendicular osteosarcomas. J Vet Intern Med 2004, 18, 859–865. Mullins M.N. Lana S.E. Dernell W.S. Ogilvie G.K. Withrow S.J. Ehrhart E.J. Cyclooxygenase-2 expression in canine appendicular osteosarcomas J Vet Intern Med 2004 18 859 86510.1111/j.1939-1676.2004.tb02633.xSearch in Google Scholar

12Okamoto A., Shirakawa T., Bito T., Shigemura K., Hamada K., Gotoh A., Fujisawa M., Kawabata M.: Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo Urology 2008, 71, 156–160. Okamoto A. Shirakawa T. Bito T. Shigemura K. Hamada K. Gotoh A. Fujisawa M. Kawabata M. Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo Urology 2008 71 156 16010.1016/j.urology.2007.09.061Search in Google Scholar

13Pang L.Y., Argyle S.A., Kamida A., Morrison K.O., Argyle D.J.: The long-acting COX-2 inhibitor mavacoxib (Trocoxil™) has anti-proliferative and pro-apoptotic effects on canine cancer cell lines and cancer stem cells in vitro BMC Vet Res 2016, 10, 184. Pang L.Y. Argyle S.A. Kamida A. Morrison K.O. Argyle D.J. The long-acting COX-2 inhibitor mavacoxib (Trocoxil™) has anti-proliferative and pro-apoptotic effects on canine cancer cell lines and cancer stem cells in vitro BMC Vet Res 2016 10 18410.1186/PREACCEPT-9511370941246208Search in Google Scholar

14Papineni S., Chintharlapalli S., Abdelrahim M., Lee S.O., Burghardt R., Abudayyeh A., Baker C., Herrera L., Safe S.: Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis 2009, 30, 1193–1201. Papineni S. Chintharlapalli S. Abdelrahim M. Lee S.O. Burghardt R. Abudayyeh A. Baker C. Herrera L. Safe S. Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met Carcinogenesis 2009 30 1193 120110.1093/carcin/bgp092Search in Google Scholar

15Rosenberger J.A., Pablo N.V., Crawford P.C.: Prevalence of and intrinsic risk factors for appendicular osteosarcoma in dogs: 179 cases (1996–2005). J Am Vet Med Assoc 2007, 231, 1076–1080. Rosenberger J.A. Pablo N.V. Crawford P.C. Prevalence of and intrinsic risk factors for appendicular osteosarcoma in dogs: 179 cases (1996–2005) J Am Vet Med Assoc 2007 231 1076 108010.2460/javma.231.7.1076Search in Google Scholar

16Roze M., Thomas E., Davot J.L.: Tolfenamic acid in the control of ocular inflammation in the dog: pharmacokinetics, and clinical results obtained in an experimental model. J Small Anim Pract 1996, 37, 371–375. Roze M. Thomas E. Davot J.L. Tolfenamic acid in the control of ocular inflammation in the dog: pharmacokinetics, and clinical results obtained in an experimental model J Small Anim Pract 1996 37 371 37510.1111/j.1748-5827.1996.tb02418.xSearch in Google Scholar

17Ru G., Terracini B., Glickman L.T.: Host related risk factors for canine osteosarcoma. Vet J 1998, 156, 31–39. Ru G. Terracini B. Glickman L.T. Host related risk factors for canine osteosarcoma Vet J 1998 156 31 3910.1016/S1090-0233(98)80059-2Search in Google Scholar

18Shigemura K., Shirakawa T., Wada Y., Kamidono S., Fujisawa M., Gotoh A.: Antitumor effects of etodolac, a selective cyclooxygenase-II inhibitor, against human prostate cancer cell lines in vitro and in vivo Urology 2005, 66, 1239–1244. Shigemura K. Shirakawa T. Wada Y. Kamidono S. Fujisawa M. Gotoh A. Antitumor effects of etodolac, a selective cyclooxygenase-II inhibitor, against human prostate cancer cell lines in vitro and in vivo Urology 2005 66 1239 124410.1016/j.urology.2005.06.07616360450Search in Google Scholar

19Spodnick G.J., Berg J., Rand W.M., Schelling S.H., Couto G., Harvey H.J., Henderson R.A., MacEwen G., Mauldin N., McCaw D.L.: Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978–1988). J Am Vet Med Assoc 1992, 200, 995–999. Spodnick G.J. Berg J. Rand W.M. Schelling S.H. Couto G. Harvey H.J. Henderson R.A. MacEwen G. Mauldin N. McCaw D.L. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978–1988) J Am Vet Med Assoc 1992 200 995 999Search in Google Scholar

20Wilson H., Chadalapaka G., Jutooru I., Sheppard S., Pfent C., Safe S.: Effect of tolfenamic acid on canine cancer cell proliferation, specificity protein (Sp) transcription factors, and Sp-regulated proteins in canine osteosarcoma, mammary carcinoma, and melanoma cells. J Vet Intern Med 2012, 26, 977–986. Wilson H. Chadalapaka G. Jutooru I. Sheppard S. Pfent C. Safe S. Effect of tolfenamic acid on canine cancer cell proliferation, specificity protein (Sp) transcription factors, and Sp-regulated proteins in canine osteosarcoma, mammary carcinoma, and melanoma cells J Vet Intern Med 2012 26 977 98610.1111/j.1939-1676.2012.00931.x490653622536857Search in Google Scholar

21Withrow S.J., Vail M.D.: Withrow and MacEwen’s Small Animal Clinical Oncology, edited by S.J. Withrow, D.M. Vail, W.B. Saunders, St. Louis, 2007, p. 71. Withrow S.J. Vail M.D. Withrow and MacEwen’s Small Animal Clinical Oncology edited by WithrowS.J. VailD.M. SaundersW.B. St. Louis 2007 p 7110.1016/B978-072160558-6.50013-7Search in Google Scholar